



## (51) International Patent Classification:

*C07D 401/08* (2006.01) *A61K 31/439* (2006.01)  
*C07D 451/04* (2006.01) *A61P 25/28* (2006.01)  
*C07B 59/00* (2006.01)

## (21) International Application Number:

PCT/GB2013/052442

## (22) International Filing Date:

18 September 2013 (18.09.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/702,330 18 September 2012 (18.09.2012) US  
 61/823,606 15 May 2013 (15.05.2013) US

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**  
 [GB/GB]; BioPark, Broadwater Road, Welwyn Garden  
 City, Hertfordshire AL7 3AX (GB).

(72) Inventors: **BROWN, Giles Albert**; c/o Heptares Thera-  
 peutics Limited, BioPark, Broadwater Road, Welwyn  
 Garden City, Hertfordshire AL7 3AX (GB). **CANSFIELD,  
 Julie Elaine**; c/o Heptares Therapeutics Limited, BioPark,

Broadwater Road, Welwyn Garden City, Hertfordshire  
 AL7 3AX (GB). **CONGREVE, Miles Stuart**; c/o  
 Heptares Therapeutics Limited, BioPark, Broadwater  
 Road, Welwyn Garden City, Hertfordshire AL7 3AX (GB).  
**PICKWORTH, Mark**; c/o Heptares Therapeutics Lim-  
 ited, BioPark, Broadwater Road, Welwyn Garden City,  
 Hertfordshire AL7 3AX (GB). **TEHAN, Benjamin Ger-  
 ald**; c/o Heptares Therapeutics Limited, BioPark, Broad-  
 water Road, Welwyn Garden City, Hertfordshire AL7 3AX  
 (GB).

(74) Agent: **STRATAGEM IPM LIMITED**; Fosters Wing,  
 Anstey Hall, Maris Lane, Trumpington, Cambridge, Cam-  
 bridgeshire CB2 9LG (GB).

(81) Designated States (unless otherwise indicated, for every  
 kind of national protection available): AE, AG, AL, AM,  
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,  
 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS





Figure 1



(57) Abstract: This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R<sub>1</sub>-R<sub>5</sub>, X<sub>1</sub>, X<sub>2</sub> and p are as defined herein.



TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report (Art. 21(3))